Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Checkpoint Therapeutics Inc CKPT

Healthcare Biotechnology
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber... see more

Recent & Breaking News (NDAQ:CKPT)

Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

GlobeNewswire October 5, 2017

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

GlobeNewswire September 20, 2017

Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

GlobeNewswire September 11, 2017

Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire September 5, 2017

Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market

GlobeNewswire June 26, 2017

Checkpoint Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

GlobeNewswire June 1, 2017

Checkpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

GlobeNewswire April 27, 2017

Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs

GlobeNewswire April 4, 2017

Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

GlobeNewswire March 20, 2017

Checkpoint Therapeutics to Present at the 29th Annual ROTH Conference

GlobeNewswire March 9, 2017

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

GlobeNewswire February 28, 2017